Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Recruiting 3Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 19OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 5von Hippel-Lindau Disease 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Hemangioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1

Interventions

Nivolumab 74Sunitinib 73pembrolizumab 49Everolimus 39Sorafenib 36Bevacizumab 36Axitinib 36cabozantinib 35Radiosurgery 33Ipilimumab 33pazopanib 32Magnetic Resonance Spectroscopy 27Interleukin-2 27aldesleukin 23Specimen Handling 22Cyclophosphamide 21lenvatinib 20fludarabine phosphate 17Radiotherapy 16Interferon-alpha 15Peripheral Blood Stem Cell Transplantation 14Gemcitabine 14Biopsy 14temsirolimus 13Nephrectomy 13durvalumab 11Immunohistochemistry 11CTLA-4 Antigen 11Blood Specimen Collection 11Capecitabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Renal Cell × belzutifan × Clear all
NCT07023432 2026-05-22

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

M.D. Anderson Cancer Center

Phase 2 Recruiting
78 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07593040 2026-05-20

Moonlanding

Vall d'Hebron Institute of Oncology

Phase 2 Not yet recruiting
150 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07187778 2026-01-05

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

M.D. Anderson Cancer Center

Phase 2 Recruiting
10 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07167329 2025-09-11

BELIEVE-VHL

AC Camargo Cancer Center

Phase 2 Recruiting
100 enrolled
CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT04627064 2025-07-25

ABEMA Alone or in COMBO With MK-6482

Dana-Farber Cancer Institute

Phase 1 Completed
11 enrolled 9 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡